{"links":{"html":"https://www.erudio.com/reports/paxipem-nct05096390","json":"https://www.erudio.com/reports/paxipem-nct05096390.json","markdown":"https://www.erudio.com/reports/paxipem-nct05096390.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"paxipem-05096390"}},"request":"https://www.erudio.com/contact?report=paxipem-05096390"},"offer":{"cited_commentary_sources":8,"verified_hcp_statements":70,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":6,"optional":true,"price_per_verified_person_usd":15,"price_usd":90,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"paxipem-nct05096390"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=paxipem-05096390","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/paxipem-nct05096390","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T08:05:33.326884Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":7,"no_commentary_found":3},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Efficacy of axitinib + pembrolizumab versus axitinib in patients with locally advanced or metastatic type 2 papillary renal carcinoma in first-line treatment."},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":10,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":2,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":10,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":9,"coverage":"discussed","id":"A1","source_count":3,"title":"First-line positioning, alternative regimens and the unresolved standard"},{"claim_count":5,"coverage":"discussed","id":"A2","source_count":2,"title":"Trial feasibility, reimbursement, referral and patient support"},{"claim_count":10,"coverage":"discussed","id":"A3","source_count":3,"title":"Portfolio expectations, biological development and translational value"},{"claim_count":6,"coverage":"discussed","id":"A4","source_count":2,"title":"Rare-disease development incentives, collaborative routes and research collections"}],"counts":{"cited_sources":9,"claims_by_expression_type":{"comparison":1,"experience":6,"interpretation":8,"opinion":38,"primary_context":1,"question":6,"uncertainty":7,"unspecified":3},"claims_by_kind":{"protocol_statement":1,"source_observation":69},"clinician_statements":24,"evidence_units":81,"findings":7,"organisational_accounts":1,"people_cited":8,"people_identity_verified":6,"people_total":8,"screened_sources":24,"verified_claims":70},"findings_index":[{"id":"F1","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":5},"has_counterview":true,"limitations":3,"links":{"context":2,"support":6},"ma_question":true,"named_voices":5,"passages":6,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"PAXIPEM attracts interest, but its axitinib rationale receives a specific, tentative reservation"},{"id":"F2","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":1,"views":7},"has_counterview":true,"limitations":3,"links":{"context":1,"support":13},"ma_question":true,"named_voices":4,"passages":13,"sources":6,"sources_by_kind":{"commentary":2,"media":3,"registry":1}},"title":"The demand for randomization is about incremental benefit and harm, with a qualified role for homogeneous single-arm studies"},{"id":"F3","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":0,"views":4},"has_counterview":true,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":4,"passages":7,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"The competing upfront regimen preferences remain conditional and do not establish a standard"},{"id":"F4","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":0,"views":5},"has_counterview":true,"limitations":3,"links":{"context":2,"support":7},"ma_question":true,"named_voices":2,"passages":6,"sources":3,"sources_by_kind":{"media":3}},"title":"Trial-first preferences have practical exceptions, including a narrowly conditional monotherapy option"},{"id":"F5","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":2,"questions":2,"restated":2,"views":4},"has_counterview":true,"limitations":3,"links":{"context":2,"support":13},"ma_question":true,"named_voices":3,"passages":11,"sources":3,"sources_by_kind":{"media":3}},"title":"Histology-specific treatment requires diagnostic clarity, but pathology re-review is selective rather than universal"},{"id":"F6","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":8},"has_counterview":true,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":3,"passages":7,"sources":4,"sources_by_kind":{"commentary":2,"media":2}},"title":"The portfolio is viewed as potentially consequential, while its biological novelty remains debated"},{"id":"F7","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":5},"has_counterview":true,"limitations":4,"links":{"context":0,"support":8},"ma_question":true,"named_voices":1,"passages":5,"sources":2,"sources_by_kind":{"media":2}},"title":"Existing labels are seen as a barrier, while cooperative groups, partnerships and tissue databanks are valued"}],"medical_affairs_question":"What evidence would demonstrate a clinically meaningful net benefit from adding pembrolizumab to axitinib in this population, and how should that uncertainty be discussed when treatment choice and trial access remain conditional?","sections":{"analysis":[{"id":"section-1","level":2,"title":"PAXIPEM's rationale is questioned tentatively, not dismissed"},{"id":"section-2","level":2,"title":"The proof standard concerns added benefit and harm—not response rates alone"},{"id":"section-3","level":2,"title":"The upfront IO–IO versus IO–TKI choice remains conditional"},{"id":"section-4","level":2,"title":"Trial-first preferences encounter access, willingness and treatment-need limits"},{"id":"section-5","level":2,"title":"Histology and selective pathology review shape interpretation and eligibility discussions"},{"id":"section-6","level":2,"title":"Portfolio optimism does not equal a PAXIPEM efficacy conclusion"},{"id":"section-7","level":2,"title":"Existing broad labels are seen as a barrier to new evidence"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Efficacy of axitinib + pembrolizumab versus axitinib in patients with locally advanced or metastatic type 2 papillary renal carcinoma in first-line treatment."},{"findings":[],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F5","shared_claims":10}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T4","label":"The comparison"},{"findings":[],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":9},{"id":"F6","shared_claims":2}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T08:05:33.326884Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T08:20:09Z","record_hash":"3bfd2ae67d665e66e5889752cbab7e70c461ed4aedccedc2348feec887a5ebaa","release_hash":"a3e120be915466a97459a70440d00629178c0c5ab2d82d58066448c264efc3eb","report_id":"erudio-nct05096390","run_id":"6a651cd9-d942-4b61-ba9d-2ed0f0b11d50","schema_version":"5.0","slug":"paxipem-05096390","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"PAXIPEM asks whether adding pembrolizumab to axitinib improves first-line treatment for locally advanced or metastatic type 2 papillary renal cell carcinoma. Commentary comes from X posts, podcasts featuring medical oncologists, and a YouTube roundtable. The discussion turns on how to assess the axitinib rationale amid interest in PAXIPEM and one podcast speaker’s tentative reservation, and whether the papillary RCC trial portfolio can deliver consequential progress while its biological novelty remains debated.","meta_description":"24 sources screened · 70 verified statements (24 from clinicians verified by NPI or staff page) from 9 sources · 7 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-a9e3c7aca1480afe0af2"],"id":"F1","paraphrase":"A podcast panel addressed the question of disease-specific support for choosing axitinib as the backbone for PAXIPEM’s treatment comparison.","publication_caveats":{"reason":"Publication caveats are not specified for this source.","status":"not_set"},"source_channel":"podcast","source_date":"2025-03-15","title":"PAXIPEM attracts interest, but its axitinib rationale receives a specific, tentative reservation"},{"cited_claim_ids":["claim-ce7896838d121eece933","claim-b0f43b52322098466235","claim-07047d552ff1cd96969e"],"id":"F6","paraphrase":"A YouTube roundtable discussed what clinical and biological questions prospective papillary RCC studies, including PAXIPEM, could address.","publication_caveats":{"reason":"Publication caveats are not specified for this source.","status":"not_set"},"source_channel":"youtube","source_date":"2024-06-17","title":"The portfolio is viewed as potentially consequential, while its biological novelty remains debated"}]},"publication":{"approved_at":"2026-10-31T08:20:09Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":24},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on biomarker-selected checkpoint and targeted combination therapy in advanced papillary kidney cancer, with small-study uncertainty.","Not yet captured in this edition: a remark on patient-facing trial-finding tools supporting access to papillary kidney cancer research.","Not yet captured in this edition: a view on uncertainty over appropriate control arms for systemic-treatment trials in advanced papillary renal cell carcinoma.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","128 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition contain no PAXIPEM outcome data or exact-trial results publication. No separate protocol document or exact product-label documents for either trial drug were available; registry descriptions are planned methods, not observed efficacy or safety.","Several podcast editions reproduce the same panel, and social posts were reposted. Source totals cannot be interpreted as numbers of independent HCPs, endorsements or a measure of consensus.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Many statements concern metastatic papillary or broader non-clear-cell RCC. Approximate cross-histology figures and preferences for alternative regimens are not type 2 papillary-specific estimates or PAXIPEM comparative findings.","Regulatory history, reimbursement experience, guideline-access expectations, future practice impact and biological-development forecasts remain the speakers' recollections, interpretations or hopes.","Publication and post dates do not establish trial readout dates, session timing or changes of mind across settings.","This report does not detail organization-specific trial-navigation resources or proposals linking molecular and biobank data with institutional treatment experience, including AI-enabled analysis. Its account of participation support and translational strategy is therefore incomplete."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":3,"publication":0,"registry":1,"regulatory":0,"x_thread":4,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":8,"methods":1},"count":9,"evidence_window":{"end":"2025-07-17","start":"2023-02-09"},"retrieval_snapshot":"2026-10-31T06:54:56.373375Z","timeline":[{"count":1,"week":"2023-W06"},{"count":1,"week":"2023-W08"},{"count":1,"week":"2024-W25"},{"count":1,"week":"2024-W37"},{"count":3,"week":"2025-W11"},{"count":1,"week":"2025-W29"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05096390:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05096390:context","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:098639","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:11b255","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6f1737","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1623810737356562432:1713cf13-fde8-4394-919a-c3d39c0be05f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1628229348238196736:2a0adf93-001c-465a-acac-62a12ffe4b35","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797725864584437884:2a5439ca-ce0b-4014-8fbb-f236fae941d8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797727070761660798:61745da9-c276-41e9-811e-42d471431917","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797730179747582127:29632733-dfcf-42c7-b1f8-e1ec1fbebcd3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1811762421859524928:82f2658d-d313-4534-aa10-c9977cd59d7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834939807715279190:362df1b2-122b-4e70-a77b-9dac6feeb8d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835251770152337893:a66d0341-0037-46e2-b475-e38618a7527e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835278237481504804:86ef681e-8fa1-476c-bb55-b05c9bb1a45a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1854927652303380847:d1fdedc5-c491-4c3b-a7b0-a92a14172cce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1854935463938658719:11aef6c0-3038-4f88-9465-9c6bfc2aca21","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1945830639388987492:f50935a2-e187-4454-bde9-198d200cde5a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1945877507342766098:95b137fe-2038-42e6-8f30-87bcd8247253","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1986571321673650665:ca51e26f-7dc8-4eb5-897a-ef9ebe80c282","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1986572131635724345:5c88ef77-ff67-4ecf-bb2d-6fa863313ad9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1991798961699455060:ab9722a3-3d82-4935-9d5e-b754cb987a36","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1991800148620612066:1e2191a4-df60-4a4a-af9e-5e6bdfb548df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2007347179107852633:8334e6a5-8ab0-4ce8-b0db-ead2dcae3c19","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2007385134207775004:76369320-82b3-4e6e-853d-83345d205bc0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114369635776655704:6d3040d2-5f69-4f57-88a3-68085d972070","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:QfR5Fo0ixZI","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":20,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":24},"count":24,"evidence_window":{"end":"2026-10-25","start":"2023-02-09"},"retrieval_snapshot":"2026-10-31T06:54:56.373375Z","timeline":[{"count":1,"week":"2023-W06"},{"count":1,"week":"2023-W08"},{"count":3,"week":"2024-W23"},{"count":1,"week":"2024-W25"},{"count":1,"week":"2024-W28"},{"count":3,"week":"2024-W37"},{"count":2,"week":"2024-W45"},{"count":3,"week":"2025-W11"},{"count":2,"week":"2025-W29"},{"count":2,"week":"2025-W45"},{"count":2,"week":"2025-W47"},{"count":2,"week":"2026-W01"},{"count":1,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: axitinib oral tablet [inlyta]","status":"unmapped"},{"reason":"Unmapped registry intervention: pembrolizumab injection [keytruda]","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Papillary Renal Cell Carcinoma Type 2","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"PAXIPEM","aliases":["PAXIPEM","Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC","Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)"],"brief_title":"Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Papillary Renal Cell Carcinoma Type 2"],"display_condition":"first-line advanced papillary renal cell carcinoma type 2","display_interventions":[["axitinib","pembrolizumab"]],"enrollment":{"count":72,"type":"ESTIMATED"},"interventions":[{"name":"Axitinib Oral Tablet [Inlyta]","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pembrolizumab Injection [Keytruda]","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05096390","official_title":"Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)","overall_status":"UNKNOWN","phase":["PHASE2"],"primary_completion_date":{"date":"2024-10","type":"ESTIMATED"},"primary_endpoints":[{"description":"6-month objective response rate (6m-ORR), defined as the proportion of patients with CR or PR at 6 months","measure":"Efficacy of axitinib + pembrolizumab versus axitinib in patients with locally advanced or metastatic type 2 papillary renal carcinoma in first-line treatment.","timeFrame":"At 6 months for each patient"}],"registered_date":{"date":"2021-10-27","type":"ACTUAL"},"registry_last_updated":"2024-01-25","registry_url":"https://clinicaltrials.gov/study/NCT05096390","short_name":"PAXIPEM","short_name_basis":"registry_acronym","sponsor":"Centre Leon Berard","start_date":{"date":"2022-06-01","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2","study_ids":[{"id":"PAXIPEM (ET21-023)","type":"sponsor_study_id"},{"domain":"Centre Leon Berard","id":"ET21-023","type":"other"}],"study_type":"INTERVENTIONAL"}}}